Table 5 Prostate cancer risk and HAA intake stratified by NAT2-imputed phenotype and CYP1A1 and CYP1A2 genotype

 Rapid or intermediate acetylator

 Cases/Controls

92/124

100/116

132/93

 OR (95% CI)^a

1.00

1.17 (0.84–1.65)

1.85 (1.34–2.56)

 Slow acetylator

 Cases/Controls

8/7

8/8

11/3

 OR (95% CI)

1.43 (0.50–4.12)

1.21 (0.56–2.60)

5.29 (2.37–11.80)

 AA

  Cases/controls

51/87

68/82

88/63

  OR (95% CI)

1.00

1.46 (0.95–2.24)

2.41 (1.61–3.63)

 GA + GG

  Cases/controls

49/44

40/42

55/33

  OR (95% CI)

2.05 (1.19–3.63)

1.72 (1.07–2.76)

2.86 (1.83–4.47)

 CC

  Cases/controls

7/17

14/17

13/13

  OR (95% CI)

1.00

2.05 (0.73–5.77)

2.65 (0.97–7.29)

 CA + AA

  Cases/controls

93/114

94/107

130/83

 OR (95% CI)

2.17 (0.85–5.59)

2.34 (0.93–5.92)

4.01 (1.60–10.05)